Despite a large number of neuroimaging studies in schizophrenia reporting subtle brain abnormalities, we do not know to what extent such abnormalities reflect the effects of antipsychotic treatment on brain structure. We therefore systematically reviewed cross-sectional and follow-up structural brain imaging studies of patients with schizophrenia treated with antipsychotics. 30 magnetic resonance imaging (MRI) studies were identified, 24 of them being longitudinal and six cross-sectional structural imaging studies. In patients with schizophrenia treated with antipsychotics, reduced gray matter volume was described, particularly in the frontal and temporal lobes. Structural neuroimaging studies indicate that treatment with typical as well as atypical antipsychotics may affect regional gray matter (GM) volume. In particular, typical antipsychotics led to increased gray matter volume of the basal ganglia, while atypical antipsychotics reversed this effect after switching. Atypical antipsychotics, however, seem to have no effect on basal ganglia structure.
INTRODUCTION
Schizophrenia is a severe psychiatric disorder that affects about 1% of the population and is one of the top ten causes of disability worldwide [1] . Despite decades of research the neurobiological basis of schizophrenia is still largely unknown [2] . However, modern neuroimaging techniques have enabled us to examine the brains of patients with schizophrenia in vivo. A large body of neuroimaging studies have reported that as the illness proceeds, patients rapidly lose cerebral gray matter (GM), particularly in the frontal, temporal and limbic lobes [3, 4] . The treatment of schizophrenia involves the use of antipsychotic drugs (typical antipsychotics, such as haloperidol), which act as antagonists at central dopamine D 2 receptors [5, 6] , although some of them have additional effects on other receptors [7] . A new generation of antipsychotic drugs, the atypical antipsychotics (for example quetiapine, olanzapine, risperidone and clozapine), with a lower affinity and occupancy for the dopaminergic receptors, but an additional occupancy for the serotoninergic 5-HT 2A and other receptors [8] have become available. Antipsychotics are effective in reducing the severity of positive psychotic symptoms but have limited impact on negative symptoms, cognitive impairment and produce a range of side effects including extra-pyramidal symptoms, prolactin elevation, sedation and cardio-metabolic effects [7] . Compared to typical antipsychotics, atypical antipsychotics induce less extra-pyramidal adverse effects and more metabolic adverse *Address correspondence to this author at the Psychiatric Outpatient Department, Medical Image Analysis Centre, Petersgraben 4, CH-4031 Basel, Switzerland; Tel: 0041613286126; Fax: 0041612654588; E-mail: sborgwardt@uhbs.ch effects [7] but the underlying neurobiological mechanisms are still unclear.
One way to better understand these mechanisms is to use neuroimaging to investigate structural brain changes associated with a specific class of antipsychotic drugs. Neuroimaging is a potentially powerful tool to explore the impact of antipsychotic medication on brain structure in schizophrenia. Neuroimaging studies indicate that schizophrenia is associated with neuroanatomical abnormalities, with robust evidence of reduced GM volume in a number of cerebral regions [9, 10] . In particular these studies demonstrated volumetric reductions in the whole brain, in the prefrontal cortex and in the superior and medial temporal lobes [4, [11] [12] [13] [14] . These neuroimaging findings are also supported by post-mortem studies [15, 16] .
Studies of schizophrenia and other psychiatric disorders have suggested that the ability of antipsychotic medication to induce anatomical and molecular changes in the brain may be relevant for its antipsychotic properties in addition to their action on neurotransmission [17] [18] [19] [20] [21] . However, despite considerable research, a major concern for neuroimaging studies of patients with schizophrenia is the potential confound of antipsychotic medication. Thus, it remains unclear to what extent structural changes are due to the ongoing illness process and to what extent to medication and how different antipsychotic medications affect neuroimaging measures. The aim of this article is to systematically review neuroimaging studies addressing the impact of antipsychotic medication on brain structure. In addition, we examine the different effects of typical and atypical antipsychotic medication.
Selection Criteria
First, studies that investigated brain structure and differences between groups of patients treated with typical or atypical antipsychotics were included. We hand-searched all the publications in order to find longitudinal and cross-sectional neuroimaging studies considering the effects of antipsychotic medication as well as the references of all manuscripts for further relevant publications. To qualify for inclusion in this review the studies must have: (a) been an original publication in a peer-reviewed journal (b) studying schizophrenic patients using neuroimaging techniques according to antipsychotic medication (c) considering the differences in medication either among various antipsychotic medications or over the time among various groups of patients.
According to their clinical stage, patients with schizophrenia were considered as patients with a first episode (defined as first hospitalization [22] , less than five years` total duration of disease [23] ), recent onset (first hospitalization within the last 5 years [22] ), chronic patients (disease duration greater than five years [24] , disease duration more than ten years [23] ), or therapy resistant chronic patients (chronic and refractory to conventional treatment [25] ). We used the term antipsychotic-naïve for those patients who have never used any antipsychotic medication and 'antipsychotic-free' for patients free of antipsychotic medication for at least two months before admission [26] .
Recorded Variables
One approach for systematic reviews is to survey the literature and then provide an informed interpretation of the main findings. However, with this approach the review's summarising process may be opaque to the reader, who cannot assess the validity of the conclusions without reading the original papers. In the present review we have tried to help the readers to form their own opinion by presenting a number of key quantitative measures from the studies reviewed in informative tables. Two of the authors extracted the data independently (SB and RS). The recorded variables for articles used in the review were: type of medication, mean dose of the used drugs, chlorpromazine equivalents, regional volumetric brain differences, type of study design (longitudinal/cross-sectional) and imaging analysis method (regionof-interest, voxel-based morphometry) and the demographic characteristics of patients groups.
RESULTS
In recent years a large number of neuroimaging studies have been conducted to evaluate the variations and longitudinal changes in brain structure in various groups of patients, often reporting contradictory results. 30 studies published between 1996 and 2008 met the inclusion criteria and were reviewed, 24 of them being longitudinal and six crosssectional structural imaging studies. Table 1 contains an overview of all reviewed studies for better orientation.
Structural Neuroimaging Studies
We reviewed structural MRI studies evaluating GM volume differences between patients and healthy controls (cross-sectional) as well as progressive changes (longitudinal) in whole and regional brain volumes and compared these between groups of patients according to their antipsychotic treatment.
Cross-Sectional MRI Studies
In total, six cross-sectional MRI studies were reviewed. Two cross-sectional studies compared patients treated with typical antipsychotics only to healthy controls [22, 24] and four studies compared patients treated with different antipsychotics [3, 23, 27] .
The results of Kopelman et al. suggest that patients treated with typical antipsychotics have a thicker cortical depth of the left anterior cingulate gyrus without displaying any difference in surface area compared to healthy controls [24] . In another study increasing exposure to typical antipsychotics correlated with a larger insular volume, but the differences between patients and healthy controls were not significant [22] .
Brain structural changes associated with the use of typical or atypical antipsychotics in first-episode psychosis patients are mostly qualitative, because they appear as significant in each group compared only to the drug-free group. Treatment with typical antipsychotics was associated with an enlargement of the basal ganglia and size reductions in insula, extending into inferior frontal and superior temporal gyrus, in lobulus paracentralis, anterior cingulate gyrus and precuneus [27] . However, treatment with atypical antipsychotics was associated solely with an enlargement of the thalami [27] . Pituitary volume was 30 % larger in the firstepisode patients receiving typical antipsychotics and 17% larger in patients receiving atypical antipsychotics compared to healthy controls [28] . Higher doses of a typical antipsychotic were associated with larger caudate, putamen and thalamus volumes, whereas a higher dose of an atypical antipsychotic only with larger thalamic volume [3] . Firstepisode schizophrenic patients treated with atypical antipsychotics had larger hippocampal volumes than those treated with typical antipsychotics [23] . The specifics of each of these cross-sectional MRI studies have been included in Table 2 . All studies are also referenced in the text. Abbreviations C = control; AN = antipsychotic-naïve; AF = antipsychotic free; PT = previously treated; FE = first episode; RO = recent onset; TR = treatment resistant; ChP = chronic patient; BG = basal ganglia; CPZ = chlorpromazine; CPZ E = chlorpromazine equivalent; VBM = voxel-based morphometry; ROI = region of interest; BT = before therapy; AT = after therapy; GM = gray matter.
Longitudinal MRI Studies Using Voxel-Based Morphometry (VBM)
In total, 13 longitudinal MRI studies using VBM methods were reviewed. Two studies of patients treated with typical and atypical antipsychotics did not examine the differences between subgroups of antipsychotic medication [29, 30] . Another four longitudinal studies searched for progressive changes after treatment with either of atypical antipsychotics [2, 26, 31, 32] . Seven studies evaluated the changes in brain structure after medication with only atypical antipsychotic medication [33] [34] [35] [36] [37] [38] [39] . Three studies assessed chronic patients with schizophrenia [29, 33, 34] , two studies focused on childhood-onset psychosis [38, 39] , whereas the other studies only included patients with first-episode schizophrenia [2, 26, [30] [31] [32] [35] [36] [37] . The brain changes were compared with a healthy control group comprising healthy volunteers in seven studies [26, 30, 32, 35, [37] [38] [39] .
A study that examined the effects of medication with typical antipsychotics revealed GM increases in basal ganglia volume [32] , whereas the basal ganglia volume remained unchanged following treatment with atypical antipsychotics [34] . The study by Lieberman et al. [32] is the only controlled, double blind, randomized, multi-site longitudinal study. With a relatively large sample size of seventy-nine patients with first-episode schizophrenia, patients treated with haloperidol showed significant reductions in GM volume compared to healthy controls. In contrast, olanzapine-treated patients did not show any significant decreases in GM volume during the follow up period. GM reduction in the haloperidol group was evident during the first 12 weeks in frontal GM and at week 52 in the temporal and parietal GM. Significant volume increases in the caudate nucleus in the haloperidol group were observed at weeks 24, 52 and 104 compared to olanzapine group [32] .
In another study by Thompson et [2] . The haloperidoltreated group showed the fastest tissue loss in the frontal cortex during the first year of psychosis. In the olanzapine group the brain changes occurred more posteriorly in occipital and limbic regions. These results suggest that antipsychotic medication may not be entirely protective. The volumetric changes related to antipsychotic medication are regionally much more pronounced than it would be predicted from healthy controls. However, the differences between the medication groups were less pronounced after a 12-month period [2] .
Among a small sample of patients with chronic schizophrenia, relative volume increases in left hippocampal GM were found in patients treated with atypical, but not with typical antipsychotics [29] . Patients treated with typical antipsychotics showed a trend towards decreasing total cerebrospinal fluid (CSF) volume [29] . In medication-free chronic patients treated briefly with atypical antipsychotics no significant changes in GM volume were observed [33] . Results from another study of patients with chronic schizophrenia showed greater GM density in the basal ganglia after 20 weeks of medication with quetiapine [34] . These findings were contradictory to previous short-term follow up studies [26, 29, 33] .
Individuals with first-episode psychosis, who received short-term treatment (six weeks) with risperidone, showed increased GM volume in the temporal cortex and decreased GM in frontal cortex. Risperidone-treatment was associated with reduced WM and was found in the corpus callosum, cerebellum and right anterior cingulate [35] .
In childhood-onset schizophrenia clozapine treated patients had larger caudate volume compared to healthy controls [38] . However, after two years of clozapine treatment, caudate volume did not differ between baseline and followup scan [38] . In adolescent-onset schizophrenia, smaller volumes in the prefrontal cortex and thalamus, a larger fourth ventricle volume and a reduced cerebellar (i.e. vermis) volume were found in a longitudinal study with patients treated with atypical antipsychotics [39] .
Relative to antipsychotic-naïve patients, patients receiving treatment (15 with typical, five with atypical antipsychotics) had relatively greater GM volumes in the caudate and in the cingulate gyri extending to the left medial frontal gyrus [31] after three-four weeks of treatment. Results from recently decompensated antipsychotic-free schizophrenic patients showed no evidence, that a four-week antipsychotic treatment itself may cause volumetric change in cerebral WM volume [30] . Patients with childhood-onset schizophrenia treated for two years with atypical antipsychotics showed GM reductions in parietal and fronto-temporal cortices as well as reduced total GM volume [37] . The specifics of each of these longitudinal VBM studies have been included in Table 3 .
Longitudinal Studies Using a Region-of-Interest (ROI) Approach
In total, 11 longitudinal MRI studies using ROI methods were reviewed. Seven longitudinal studies using an ROI approach focused on basal ganglia [40] [41] [42] [43] [44] [45] [46] , one on the thalamus [47] , one on the anterior cingulate gyrus [48] and two studies on other cortical regions [25, 49] . Five studies evaluated GM changes after treatment with atypical antipsychotic medication only [25, 40, 43, 45, 47] , four compared typical versus atypical antipsychotic [41, 44, 46, 48] and two did not examine for the differences between these two subtypes of antipsychotic drugs [42, 49] .
No differences between baseline and follow-up in caudate volumes were seen in a subgroup of ten patients after 12 weeks of quetiapine treatment [40] . After a five-year followup only an age-related decline in caudate volume in patients' treatment with both typical and atypical antipsychotics and healthy controls was found [41] . At the beginning the antipsychotic-naïve patients treated exclusively with atypical antipsychotics showed only a negligible volume enlargement of the caudate after two years, but these changes may be sexdependent [43] . Female patients with a greater amount of drug exposure had fewer enlargements of caudate nuclei. In males the correlation was reversed [43] . Treatment with typical antipsychotics was associated with larger basal ganglia volumes and switching to olanzapine was associated with a reduction in basal ganglia volumes [44] . Volumes of putamen and globus pallidus were normalized following the switch to olanzapine. In the group of risperidone-treated patients, who later switched to olanzapine, no significant differences in overall basal ganglia volume were seen [44] . Treatment with clozapine in schizophrenic patients previously treated with typical antipsychotics resulted in decreased caudate volume [45] . Volume of caudate and nucleus lentiformis increased after exposure to typical antipsychotics and decreased following exposure to atypical antipsychotics [46] . Caudate volumes increased in first-episode patients during 18-month treatment by 5.7% and decreased by 1.6% in healthy controls [42] .
Several other longitudinal studies in chronic and first episode treated with both typical and atypical medication have produced evidence for GM volume changes in different regions including the parietal and occipital lobes [25] and thalamic volume [49] . Exposure to typical antipsychotics was associated with an increase in anterior cingulate cortex (ACC) volume over time while exposure to the atypical class of antipsychotics was associated with a decrease in volume of ACC over time [48] . Progressive brain changes in patients with schizophrenia occur despite ongoing antipsychotic drug-treatment, however, no significant differences were AN baseline: in O GM + P GM vs C, in total + O WM vs C; longitudinally: the greater the initial deficit in total and P GM, the greater the increase in GM + the greater the initial excess total WM and its change in total and O WM, the greater the longitudinal decreases; ChP TR : in total, F GM, P and O GM vs C + in total, F, P, O WM vs C; longitudinally: the greater the baseline volume excess of WM, the greater the in total, F, P and O WM (Table 3) seen among the four different treatment groups (typical antipsychotics, atypical antipsychotics, typical + atypical antipsychotics, clozapine) [49] . The specifics of each of these longitudinal ROI studies have been included in Table 3 .
DISCUSSION
Structural neuroimaging studies can be used to examine the influence of antipsychotics on brain structure. Overall, structural imaging studies suggest that medication with typical antipsychotics leads to an increased volume of the basal ganglia, while atypical antipsychotics reduce this volume after switching.
Effects of Antipsychotic Medication on Structural Neuroimaging Measures in Schizophrenia
There is a convergence of findings from structural neuroimaging studies described showing volumetric reductions in fronto-temporo-limbic regions may reflect pathophysiologic processes of schizophrenia [9, 12] . Studies of patients with schizophrenia demonstrate robust volumetric reductions in multiple brain regions and particularly in the prefrontal cortex and of the superior and medial temporal lobes and in the anterior cingulate [4, [11] [12] [13] [14] .
While these findings are consistent and replicated, there are inconsistencies regarding the potential effect of antipsychotic medication. Some studies found no significant effect of antipsychotic medication on brain structure [30, 33, 40, 41, 49] . However, in many of these studies, the sample sizes were modest (< 30 subjects) resulting in type 2 errors. Other studies found ameliorative effects of (mostly atypical) antipsychotics on structural neuroimaging measures [38, 44, 50, 51] . Generally, both typical and atypical antipsychotics respectively the illness process itself were associated with GM volume reductions in occipital and limbic regions [2] .
In general, functional imaging studies underline findings from structural neuroimaging studies. They suggest that treatment with atypical antipsychotics has been associated with greater regional cortical activity compared to treatment with typical antipsychotic drugs, whereas the latter have been associated with relatively more striatal activity [52] . Atypical antipsychotics (substitution of risperidone for typical antipsychotic) also increased prefrontal activity (prefrontal cortex, supplementary motor area) during cognitive tasks (working memory) and reduced abnormally elevated subcortical limbic activity during emotion processing so that brain activity resembled that observed in healthy volunteers [50] . These findings might reflect pathophysiologic processes that may be at least partly ameliorated by antipsychotic medication. Clozapine but not haloperidol treatment re-established normal task-activated regional cerebral blood flow (CBF) patterns in schizophrenia in the ACC [53] . This is consistent with the finding that atypical antipsychotics might have a greater effect on cognitive impairment in schizophrenia than typical [54] . Progressive brain changes in schizophrenia are considered controversial [55] . Although there is evidence for GM loss and ventricular enlargement from prospective studies of patients with first episode and chronic schizophrenia [49, [56] [57] [58] [59] [60] [61] , the potential confounding impact of antipsychotics is still debatable. Most neuroimaging studies of schizophrenia to date have not included the examination of non-medicated patients, making conclusions about medication effects on neuroimaging measures difficult. Investigation of subjects at the onset of the disease avoids potential confounders such as antipsychotic treatment [62] [63] [64] [65] . A clinical high-risk status for psychosis (at risk mental state, ARMS) is associated with a set of neurofunctional abnormalities that are qualitatively similar to those observed in patients with the disorder [66] . As these findings are not attributable to chronic psychotic symptoms [67] and antipsychotic treatment, they may represent markers of increased vulnerability to psychotic disorders. Structural MRI studies of non-medicated patients in a prodromal phase of psychosis or ARMS demonstrated that neuroanatomical abnormalities are already evident in the very early phase of psychosis. People at high risk of psychosis show qualitatively similar volumetric abnormalities to patients with schizophrenia. Cortical brain abnormalities have been found in genetically defined high-risk populations such as first-degree relatives and co-twins of patients with schizophrenia, as well in people with ARMS [13, [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] . Previous longitudinal MRI studies in this group found that the subset of patients who developed psychosis showed a longitudinal reduction in GM in the orbito-frontal, temporal lobe, parietal lobe and cerebellum [79, 81, 82] .
Mechanisms of Antipsychotic Action on Brain Structure
At present, the mechanism of action of antipsychotics is inferred from animal and in vitro studies. Structural neuroimaging has contributed substantially to the understanding of the mechanisms of action of existing antipsychotic drugs. Thompson et al. [2] suggest pharmacologic mechanisms that go beyond symptom suppression via neuroreceptor antagonism. Those mechanisms might ameliorate the underlying pathophysiology that causes disease progression and the clinical deterioration that is the hallmark of the illness [2] .
Furthermore, it has been suggested that antipsychotics might increase neurogenesis, however, neurogenesis seems contradictory to studies showing that antipsychotics are associated with volume reductions. Haloperidol treatment may be neurotoxic [25, 83] which may explain the cortical GM volume reduction. In a very recent study, Konopaske et al. [84] found a significant 20.5% reduction in astrocyte numbers and a non-significant 12.9% reduction in oligodendrocytes in antipsychotic-exposed macaque monkeys. Similar effects were seen in both haloperidol and olanzapine treated patients. These very intriguing findings of antipsychoticinduced glial cell number reduction in animals, however, need to be replicated. In humans, treated with typical antipsychotics, frontal GM volume reduction is correlated with the dose [3] . Medication-free subjects with an ARMS show fronto-temporal tissue reduction relative to healthy controls [79, 81, 82] , suggesting that the loss process is not attributable solely to medication.
Atypical antipsychotics reduce oxidative stress [85] and stimulate the synthesis of trophic molecules [85] [86] [87] [88] . In primates, treatment with atypical antipsychotics led to prefrontal glial cell proliferation and cortical hypertrophy [89] . In rats, olanzapine stimulates glial cell division in the frontal cortex [85] . Thus, atypical antipsychotics may reduce disturbed myelination and abnormally severe dendritic pruning and/or neurotoxic ablation of synapses [49, 90, 91] in patients with schizophrenia. Atypical antipsychotics may also induce oligodendrocyte proliferation and compensate for oligodendrocyte reductions [49] and intracortical myelination [90] .
Methodological Issues in Studies Investigating Medication Effects by Neuroimaging
Some studies used VBM, a technique that allows comparisons of the entire brain volume at the single voxel level. Mostly, an 'optimized' VBM method [92] is used to minimize the potentially confounding effects of errors in stereotactic normalization was used. It is important to note that to identify regional differences in GM volume instead of GM concentration, 'modulated' versions of VBM, which involves the multiplication of the spatially normalized GM by its relative volume before and after warping, were used. However, the use of VBM implicates problems of brain registration [93] . The size of the smoothing kernel is also relevant, because it should be roughly the size of the expected findings. Although the exact meaning of the volumetric abnormalities is not entirely clear, GM reductions may reflect a variety of neuropathological changes, e.g. exaggerated dendritic or synaptic pruning [94] , impaired myelination [90] , apoptosis [95] , or other neurotoxic effects of first-generation antipsychotic medications [96] . Furthermore, differences in scanning parameters and image analysis may account for inconsistencies in neuroimaging measures.
The results of this review raise ethical questions on antipsychotic use. If antipsychotic medication may lead -at least in some patients -to GM volume reduction careful benefitrisk decisions have to be made for individual patients. Patients with schizophrenia should be very cautiously informed about the potential risks (and of course benefits) of antipsychotic medication.
For future studies, we suggest to focus on, longitudinal designs that represent the gold standard for investigation of medication effects. These studies have clearly the advantage of powerful, within-subject designs. Small sample sizes, heterogeneity in the sociodemographic characteristics of the subjects, lack of consistency between scanning parameters also suggest future multi-site studies that have shown the potential to overcome most of these problems and to bridge basic neuroscience with clinical psychiatry.
CONCLUSIONS
In patients with schizophrenia treated with antipsychotics, reduced GM volume is described, particularly in frontal and temporal lobes. Medication with typical antipsychotics also leads to increased volume of the basal ganglia, while atypical antipsychotics reversed the effect after switching.
Neuroimaging studies have provided compelling evidence that despite antipsychotic medication (both typical and atypical) there are detectable anatomical changes at the level of total and regional brain volumes. To date, it remains elusive whether the effects of antipsychotic medication on GM volume are simply beneficial. It is questionable whether the effects we are observing are the direct effects of antipsychotics or whether these measures are actually surrogates for third variables. It is also possible that the opposite could be true, that antipsychotics may attenuate the brain changes and that compliance with medication could lead to less progressive change than non-compliance. Unless we do not have more reliable studies from non-medicated patients, the potential impact of the confounding effect of medication has to be kept in mind. So far, the investigation of patients at risk or with a first-episode of schizophrenia seems to be the most promising alternative.
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